DSpace Repository

Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals

Show simple item record

dc.contributor Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Carrillo, Jorge
dc.contributor.author Molinos-Albert, Luis M.
dc.contributor.author Rodríguez de la Concepción, Maria L.
dc.contributor.author Marfil, Sílvia
dc.contributor.author García, Elisabet
dc.contributor.author Derking, Ronald
dc.contributor.author Sanders, Rogier W.
dc.contributor.author Clotet, Bonaventura
dc.contributor.author Blanco, Julià
dc.date.accessioned 2015-04-17T07:16:08Z
dc.date.available 2015-04-17T07:16:08Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Carrillo, J., Molinos-Albert, L. M., De La Concepción, M. L. R., Marfil, S., Garciá, E., Derking, R., et al. (2015). Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals. Plos One, 10(3) ca_ES
dc.identifier.issn 1932-6203
dc.identifier.uri http://hdl.handle.net/10854/3993
dc.description.abstract Antibodies with the ability to block the interaction of HIV-1 envelope glycoprotein (Env) gp120 with CD4, including those overlapping the CD4 binding site (CD4bs antibodies), can protect from infection by HIV-1, and their elicitation may be an interesting goal for any vaccination strategy. To identify gp120/CD4 blocking antibodies in plasma samples from HIV-1 infected individuals we have developed a competitive flow cytometry-based functional assay. In a cohort of treatment-naïve chronically infected patients, we showed that gp120/ CD4 blocking antibodies were frequently elicited (detected in 97% plasma samples) and correlated with binding to trimeric HIV-1 envelope glycoproteins. However, no correlation was observed between functional CD4 binding blockade data and titer of CD4bs antibodies determined by ELISA using resurfaced gp120 proteins. Consistently, plasma samples lacking CD4bs antibodies were able to block the interaction between gp120 and its receptor, indicating that antibodies recognizing other epitopes, such as PGT126 and PG16, can also play the same role. Antibodies blocking CD4 binding increased over time and correlated positively with the capacity of plasma samples to neutralize the laboratory-adapted NL4.3 and BaL virus isolates, suggesting their potential contribution to the neutralizing workforce of plasma in vivo. Determining whether this response can be boosted to achieve broadly neutralizing antibodies may provide valuable information for the design of new strategies aimed to improve the anti-HIV-1 humoral response and to develop a successful HIV- 1 vaccine. ca_ES
dc.format application/pdf
dc.format.extent 18 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Plos One ca_ES
dc.rights Aquest document està subjecte a aquesta llicència Creative Commons ca_ES
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ ca_ES
dc.subject.other Sida -- Tractament ca_ES
dc.subject.other VIH (Virus) ca_ES
dc.title Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1371/journal.pone.0120648
dc.relation.publisherversion http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120648
dc.rights.accesRights info:eu-repo/semantics/openAccess ca_ES
dc.type.version info:eu-repo/acceptedVersion ca_ES
dc.indexacio Indexat a SCOPUS ca_ES
dc.indexacio Indexat a WOS/JCR

Files in this item

Show simple item record

Aquest document està subjecte a aquesta llicència Creative Commons Except where otherwise noted, this item's license is described as Aquest document està subjecte a aquesta llicència Creative Commons

Search RIUVic


Browse

Statistics